Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPrime Therapeutics Tezspire Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentPrime TherapeuticsPolicy N/A

    Tezspire Prior Authorization with Quantity Limit Program Summary

    Customize your policy alerts

    Sign up for all prime_therapeutics policy alerts

    Know when prime_therapeutics releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization, renewal, and quantity-limit approval for Tezspire (tezepelumab-ekko) 210 mg/1.91 mL subcutaneous auto-injector for Boeing commercial members. Coverage requires diagnosis-specific clinical criteria, appropriate concurrent therapy, specialist involvement, and avoidance of prohibited concomitant immunomodulatory agents.

    Policy Summary
    PayerPrime Therapeutics
    PolicyTezspire Prior Authorization with Quantity Limit Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateSep 15, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation showing diagnosis-specific criteria, required background therapy, specialist oversight, acceptable concomitant use, and no FDA-labeled contraindication.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    210 mg/1.91 mLTezspire strength
    1 pen/28 daysProgram quantity limit
    12 monthsApproval duration
    Asthma or CRSwNPCovered indications

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    90 daysTreatment window
    No prohibited immunomodulatorConcurrent-therapy restriction

    Coverage Criteria

    Initial Therapy

    Covered for initial therapy when ALL applicable requirements are met.

    ALL of the following

    • ONE of the following

      • Continuation eligibility

        • The requested agent is eligible for continuation of therapy, and the patient has been treated with the requested agent within the past 90 days (starting on samples is not approvable) and is at risk if therapy is changed.
      • New initial evaluation

        • ONE of the following diagnoses

          • Severe asthma

            • The patient has a diagnosis of severe asthma.
            • ONE of the following

              • The patient has a history of uncontrolled asthma while on asthma control therapy (e.g., inhaled corticosteroid [ICS]/long-acting beta-2 agonist [LABA] combination therapy), demonstrated by two or more severe asthma exacerbations requiring systemic corticosteroid treatment within the past 12 months.
              • The patient has one or more serious asthma exacerbations requiring hospitalization, mechanical ventilation, or a visit to the emergency room or urgent care within the past 12 months.
              • Controlled asthma worsens when the doses of inhaled and/or systemic corticosteroids are tapered.
              • Baseline, prior to therapy with the requested agent, Forced Expiratory Volume (FEV1) is less than 80% of predicted.< 80% predicted
            • The patient's medication history, excluding sample use, indicates use of a biologic immunomodulator agent that is FDA labeled or supported in compendia for the treatment of asthma within the past 12 months.
          • Chronic rhinosinusitis with nasal polyps (CRSwNP)

            • The patient has a diagnosis of chronic rhinosinusitis with nasal polyps (CRSwNP).
            • ONE of the following symptom groups

              • At least TWO adult symptoms

                • Nasal discharge (rhinorrhea or post-nasal drainage).
                • Nasal obstruction or congestion.
                • Facial pressure or pain.
                • Loss or decreased sense of smell (hyposmia).
              • At least TWO pediatric symptoms

        • ONE of the following age/indication requirements

          • The patient's age is within FDA labeling for the requested indication for the requested agent.
          • There is support for using the requested agent for the patient's age for the requested indication.
          • The patient has an indication supported in compendia for the requested agent and route of administration. Compendia allowed: AHFS; DrugDex level 1, 2a, or 2b evidence; or NCCN level 1, 2a, or 2b recommended use.
        • If the patient has severe asthma

          • ONE of the following asthma-control pathways

            • ALL of the following

              • The patient is not currently treated with a biologic immunomodulator agent that is FDA labeled or supported in compendia for asthma, including the requested agent.
              • The patient is currently treated with a maximally tolerated inhaled corticosteroid for at least 3 months and has been adherent for 90 days within the past 120 days.

                Chart notes required.

            • ALL of the following

              • The patient is currently treated with a biologic immunomodulator agent that is FDA labeled or supported in compendia for asthma, including the requested agent.
              • ONE of the following

        • If the patient has CRSwNP

          • The patient is currently treated with standard nasal polyp maintenance therapy (e.g., nasal saline irrigation, intranasal corticosteroids such as fluticasone nasal spray or mometasone nasal spray, or Sinuva).
          • The patient will continue standard nasal polyp maintenance therapy in combination with the requested agent.
      • The prescriber is a specialist in the area of the patient's diagnosis, or the prescriber has consulted with a specialist in that area (e.g., asthma: allergist, immunologist, or pulmonologist; CRSwNP: otolaryngologist, allergist, immunologist, or pulmonologist).
      • ONE of the following concomitant-therapy requirements

        • The patient will not use the requested agent in combination with another immunomodulatory agent.
        • ALL of the following

          • The patient will use the requested agent in combination with another immunomodulatory agent.
          • The prescribing information for the requested agent does not limit use with another immunomodulatory agent.
          • There is support for combination therapy; a submitted copy of clinical trials, phase III studies, or guidelines is required.
      • The patient does not have any FDA-labeled contraindications to the requested agent.

    Continuation and Renewal Therapy

    Covered for renewal therapy when ALL of the following are met.

    ALL of the following

    • The patient has been previously approved for the requested agent through the plan's Prior Authorization process.

      Patients not previously approved for the requested agent require initial evaluation review.

    • The patient has had clinical benefit with the requested agent.
    • If the patient has severe asthma, the patient is currently treated within the past 90 days and is compliant with asthma control therapy (e.g., ICS, ICS/LABA, LTRA, LAMA, or theophylline).

      Chart notes required.

    • If the patient has CRSwNP, the patient will continue standard nasal polyp maintenance therapy (e.g., nasal saline irrigation, intranasal corticosteroids such as fluticasone nasal spray or mometasone nasal spray, or Sinuva) in combination with the requested agent.

    The requested agent must not be used concomitantly with another immunomodulatory agent, including agents listed in the plan's “Agents NOT to be used Concomitantly” table. An exception is permitted when the prescribing information for the requested agent does not limit combination use and there is support for combination therapy, such as submitted clinical trials, phase III studies, or guidelines.

    Agents identified as not to be used concomitantly include Abrilada, Actemra, Adalimumab, Adbry, Amjevita, Anzupgo, Arcalyst, Avsola, Avtozma, Benlysta, Bimzelx, Cibinqo, Cimzia, Cinqair, Cosentyx, Cyltezo, Dupixent, Ebglyss, Enbrel, Entyvio, Exdensur, Fasenra, Hadlima, Hulio, Humira, Hyrimoz, Icotyde, Idacio, Ilaris, Ilumya, Imuldosa, Inflectra, Infliximab, Kevzara, Kineret, Leqselvi, Litfulo, Nemluvio, Nucala, Olumiant, Omlyclo, Omvoh, Opzelura, Orencia, Otezla, Otezla XR, Otulfi, Pyzchiva, Remicade, Renflexis, Rhapsido, Riabni, Rinvoq, Rituxan, Rituxan Hycela, Ruxience, Saphnelo, Selarsdi, Siliq, Simlandi, Simponi, Simponi ARIA, Skyrizi, Sotyktu, Spevigo subcutaneous injection, Starjemza, Stelara, Steqeyma, Taltz, Tezspire, Tofacitinib, Tofidence, Tremfya, Truxima, Tyenne, Tyruko, Tysabri, Ustekinumab, Velsipity, Wezlana, Xeljanz, Xeljanz XR, Xolair, Yesintek, Yuflyma, Yusimry, Zeposia, and Zymfentra.

    Coverage is excluded when the patient has any FDA-labeled contraindication to the requested agent.

    Clinical Thresholds

    Baseline FEV1
    ThresholdLess than 80% of predicted
    MeasureForced Expiratory Volume (FEV1)
    TimingBaseline, prior to therapy with the requested agent
    Severe asthma exacerbations
    ThresholdTwo or more exacerbations
    TimeframeWithin the past 12 months
    Treatment requiredSystemic corticosteroid treatment, also called a steroid burst

    Prior Authorization and Provider Guidance

    Prior Authorization

    Initial Prior Authorization Required

    Initial prior authorization is required. Tezspire may be approved for 12 months when the patient meets the applicable continuation or diagnosis-specific clinical criteria, age/indication requirements, treatment requirements, specialist involvement, concomitant-therapy requirements, and contraindication screening.

    • Continuation pathway: the prescriber states the patient has been treated with Tezspire within the past 90 days, excluding samples, and is at risk if therapy is changed.
    • New-start pathway: the patient has severe asthma or chronic rhinosinusitis with nasal polyps (CRSwNP) and meets all applicable clinical requirements.
    • For an FDA-labeled indication, the patient's age must be within labeling, supported for the requested age, or supported by compendia for the requested agent and route.
    • The prescriber must be an appropriate specialist or have consulted with one.
    • The patient must not use Tezspire with another immunomodulatory agent unless the prescribing information permits the combination and supporting clinical-trial, phase III, or guideline evidence is submitted.
    • The patient must have no FDA-labeled contraindication to Tezspire.

    Therapy Background

    Tezspire (tezepelumab-ekko) is a biologic administered by subcutaneous injection for the covered indications of severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). The policy evaluates disease control, controller-therapy history and adherence, maintenance treatment, specialist oversight, concomitant immunomodulator use, and contraindications.

    Clinical Definitions

    Severe asthma exacerbation
    DefinitionAn asthma exacerbation requiring treatment with a systemic corticosteroid
    Also calledA steroid burst
    Clinical contextUsed to demonstrate uncontrolled asthma while on asthma-control therapy
    Serious asthma exacerbation
    DefinitionAn asthma exacerbation requiring hospitalization, mechanical ventilation, or an emergency-room or urgent-care visit
    HospitalizationQualifying treatment setting
    Emergency treatment

    Tezspire Initial Therapy

    Tezspire Initial Therapy

    Initial Tezspire approval requires either an eligible continuation pathway or all applicable new-start requirements.

    Initial Tezspire approval

    • Eligible continuation

      • The patient has been treated with Tezspire within the past 90 days, excluding sample use, and is at risk if therapy is changed.within the past 90 days

        Starting on samples is not approvable.

    • New-start requirements

      • Covered indication

        • Severe asthma

          • Disease activity or lung-function criterion

    Tezspire Renewal

    Tezspire Renewal

    Tezspire renewal requires all of the following conditions.

    Tezspire renewal

    • The patient was previously approved for Tezspire through the plan's prior authorization process.

      Patients not previously approved through the plan require initial evaluation review.

    • The patient has demonstrated clinical benefit with Tezspire.
    • For severe asthma, the patient is currently treated within the past 90 days and is compliant with asthma-control therapy, such as an inhaled corticosteroid, ICS/LABA, LTRA, LAMA, or theophylline.within the past 90 days

      Chart notes required.

    Tezspire Quantity Limit

    Quantity limit
    Strength210 mg/1.91 mL
    Dose formSubcutaneous solution auto-injector pen
    Program quantity limit1 pen per 28 days
    Policy Summary
    PayerPrime Therapeutics
    PolicyTezspire Prior Authorization with Quantity Limit Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateSep 15, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation showing diagnosis-specific criteria, required background therapy, specialist oversight, acceptable concomitant use, and no FDA-labeled contraindication.
    SourceLink
    On This Page
    Coverage CriteriaClinical ThresholdsPrior Authorization and Provider GuidanceTherapy BackgroundClinical DefinitionsTezspire Initial TherapyTezspire RenewalTezspire Quantity Limit
  1. Nasal discharge (rhinorrhea or post-nasal drainage).
  2. Nasal obstruction or congestion.
  3. Facial pressure or pain.
  4. Cough.
  5. The patient has had symptoms consistent with chronic rhinosinusitis for at least 12 consecutive weeks.>= 12 consecutive weeks
  6. ONE of the following confirms the diagnosis

    • Anterior rhinoscopy.
    • Nasal endoscopy.
    • Computed tomography (CT) of the sinuses.
  7. The patient has tried and had an inadequate response to one intranasal corticosteroid (e.g., fluticasone nasal spray).
  8. The patient is currently treated with an adequately dosed inhaled corticosteroid for at least 3 months and has been adherent for 90 days within the past 120 days.

    Chart notes required.

  9. The patient is currently treated with a maximally tolerated inhaled corticosteroid for at least 3 months and has been adherent for 90 days within the past 120 days.

    Chart notes required.

  10. The patient has an intolerance or hypersensitivity to one inhaled corticosteroid.
  11. The patient has an FDA-labeled contraindication to all inhaled corticosteroids.
  12. ONE of the following additional controller-therapy pathways

    • The patient is currently treated for at least 3 months and has been adherent for 90 days within the past 120 days with a long-acting beta-2 agonist (LABA), long-acting muscarinic antagonist (LAMA), leukotriene receptor antagonist (LTRA), or theophylline.

      Chart notes required.

    • The patient has an intolerance or hypersensitivity to one LABA, LAMA, LTRA, or theophylline.
    • The patient has an FDA-labeled contraindication to all LABAs and all LAMAs.
  13. The patient will continue asthma control therapy (e.g., ICS, ICS/LABA, LTRA, LAMA, or theophylline) in combination with the requested agent.
  14. The prescriber is a specialist in the area of the patient's diagnosis, or the prescriber has consulted with a specialist in that area.
  15. ONE of the following concomitant-therapy requirements

    • The patient will not use the requested agent in combination with another immunomodulatory agent.
    • ALL of the following

      • The patient will use the requested agent in combination with another immunomodulatory agent.
      • The prescribing information for the requested agent does not limit use with another immunomodulatory agent.
      • There is support for combination therapy; a submitted copy of clinical trials, phase III studies, or guidelines is required.
  16. The patient does not have any FDA-labeled contraindications to the requested agent.
  17. Serious asthma exacerbations
    ThresholdOne or more exacerbations
    TimeframeWithin the past 12 months
    Qualifying treatmentHospitalization, mechanical ventilation, or a visit to the emergency room or urgent care
    CRSwNP symptom duration
    Minimum durationAt least 12 consecutive weeks
    ConditionSymptoms consistent with chronic rhinosinusitis
    Documentation contextDuration is assessed as part of the CRSwNP criteria
    Prior Authorization

    Renewal Prior Authorization

    Renewal prior authorization is required every 12 months. Renewal submissions must establish prior plan approval, documented clinical benefit, continued diagnosis-specific therapy, specialist involvement, concomitant-use compliance, and absence of contraindications.

    • The patient must have been previously approved for Tezspire through the plan's prior authorization process; patients without prior plan approval require initial evaluation.
    • Document clinical benefit from Tezspire.
    • For severe asthma, document treatment with and compliance with asthma control therapy within the past 90 days.
    • For CRSwNP, document that standard nasal polyp maintenance therapy will continue with Tezspire.
    • The prescriber must be an appropriate specialist or have consulted with one.
    • The patient must satisfy the concomitant immunomodulator and FDA-labeled contraindication requirements.
    Documentation Required

    Clinical Chart Notes and Supporting Evidence

    Submit clinical chart notes and supporting evidence with the request. Documentation must substantiate therapy history, adherence, disease control or benefit, and the requirements applicable to initial or renewal review.

    • For continuation requests, document Tezspire treatment within the past 90 days, excluding samples, and the risk associated with changing therapy.
    • For severe asthma, chart notes must document inhaled corticosteroid and other asthma-control therapy use, adequate or maximum tolerated dosing when applicable, and adherence for 90 days within the past 120 days for initial review.
    • For renewal, document current asthma-control therapy within the past 90 days and compliance.
    • Document clinical benefit with Tezspire for renewal requests.
    • If combination immunomodulator therapy is requested, submit clinical-trial, phase III, or guideline support and confirm that prescribing information does not limit the combination.
    • Include specialist consultation documentation when the prescriber is not the relevant specialist.
    Documentation Required

    CRSwNP Diagnostic Documentation

    CRSwNP requests require diagnostic documentation. The record must establish the required symptoms, duration, objective confirmation, and prior or ongoing nasal-polyp treatment.

    • Adults must have at least two of the following: nasal discharge, nasal obstruction or congestion, facial pressure or pain, or loss/decreased sense of smell.
    • Pediatric patients must have at least two of the following: nasal discharge, nasal obstruction or congestion, facial pressure or pain, or cough.
    • Symptoms consistent with chronic rhinosinusitis must have continued for at least 12 consecutive weeks.
    • Diagnosis must be confirmed by anterior rhinoscopy, nasal endoscopy, or computed tomography of the sinuses.
    • Document an inadequate response to at least one intranasal corticosteroid when required by the clinical criteria.
    • Document current standard nasal-polyp maintenance therapy and the plan to continue it with Tezspire, such as nasal saline irrigation, intranasal corticosteroids, or Sinuva.
    Documentation Required

    Severe Asthma Documentation

    Severe asthma requests require evidence of uncontrolled or otherwise qualifying disease and appropriate background treatment. Document the qualifying exacerbation history or other disease measure, controller therapy, adherence, and continuation of asthma control therapy with Tezspire.

    • Document uncontrolled asthma while on asthma-control therapy, demonstrated by at least two severe exacerbations requiring systemic corticosteroids within the past 12 months; at least one serious exacerbation requiring hospitalization, mechanical ventilation, emergency-room, or urgent-care treatment within the past 12 months; worsening controlled asthma when inhaled or systemic corticosteroids are tapered; or baseline FEV1 below 80% of predicted.
    • Alternatively, document use, excluding samples, within the past 12 months of a biologic immunomodulator that is FDA labeled or compendia-supported for asthma.
    • When no asthma biologic is being used, document a maximally tolerated inhaled corticosteroid for at least 3 months and adherence for 90 days within the past 120 days.
    • When an asthma biologic is being used, document an adequately dosed or maximally tolerated inhaled corticosteroid for at least 3 months and adherence for 90 days within the past 120 days.
    • If inhaled corticosteroids cannot be used, document intolerance or hypersensitivity to one, or an FDA-labeled contraindication to all inhaled corticosteroids.
    • Document at least 3 months of, and adherence for 90 days within the past 120 days to, a LABA, LAMA, LTRA, or theophylline, unless the applicable intolerance, hypersensitivity, or contraindication exception is met.
    • Document that asthma-control therapy will continue in combination with Tezspire.
    Denial Risk

    Failure to Meet Clinical Criteria

    Failure to satisfy a required clinical element may result in denial. The request is not approvable when the indication, required prior or background therapy, specialist involvement, or other applicable clinical requirement is absent or unsupported.

    • No qualifying severe asthma or CRSwNP diagnosis, or failure to meet the diagnosis-specific criteria.
    • No eligible continuation history and no qualifying new-start pathway.
    • Required asthma-control, intranasal, or standard maintenance therapy is absent, inadequately documented, or not continued as required.
    • Required exacerbation history, objective testing, symptom duration, diagnostic confirmation, treatment failure, adherence, or clinical documentation is missing.
    • The prescriber is neither an applicable specialist nor supported by specialist consultation.
    • The requested use does not meet FDA labeling, supported-age criteria, or accepted compendia support for the agent and route.
    • The patient fails the concomitant immunomodulator or FDA-labeled contraindication requirements.
    Denial Risk

    Prohibited Concomitant Immunomodulator

    Do not use Tezspire concomitantly with another immunomodulatory agent unless an exception is supported. Combination therapy may be considered only when the prescribing information does not limit the combination and adequate supporting evidence is submitted.

    • The default requirement is that the patient will not use Tezspire with another immunomodulatory agent, including TNF inhibitors, JAK inhibitors, or IL-4 inhibitors.
    • If combination therapy is requested, submit clinical trials, phase III studies, or guideline support for the combination.
    • The exception must satisfy both conditions: prescribing information does not limit use with the other immunomodulator, and supporting evidence is submitted.
    • The policy's agents-not-to-be-used-concomitantly list includes biologic and immunomodulatory products such as Dupixent, Fasenra, Nucala, Xolair, Tezspire, TNF inhibitors, JAK inhibitors, and other listed agents.
    Denial Risk

    FDA-Labeled Contraindication

    Tezspire is not approvable when the patient has an FDA-labeled contraindication to the requested agent. Confirm and document contraindication screening for both initial and renewal requests.

    • The initial criteria require that the patient have no FDA-labeled contraindication to Tezspire.
    • The renewal criteria likewise require that the patient have no FDA-labeled contraindication to Tezspire.
    • A documented FDA-labeled contraindication is a denial condition unless the applicable policy or labeling provides otherwise.
    Denial Risk

    Unsupported Quantity-Limit Exception

    Quantity-limit exceptions require clinical support. A requested dose or quantity above the program limit is not approvable solely because it was requested; the applicable FDA-label and evidence requirements must be documented.

    • The requested quantity must not exceed the program quantity limit, or the request must meet an exception pathway.
    • If there is no maximum FDA-labeled dose, submit support for therapy with the higher dose.
    • If the quantity does not exceed the maximum FDA-labeled dose, submit support explaining why the dose cannot be achieved with a lower quantity of a higher strength that remains within the program limit.
    • If the quantity exceeds the maximum FDA-labeled dose, submit support for therapy with the higher dose.
    • Quantity-limit approvals are for 12 months when the applicable exception criteria are met.
    Denial Risk

    Renewal Requirements Not Met

    Renewal requirements not met may result in denial. Renewal is not available when prior plan approval, documented benefit, ongoing eligible therapy, or other renewal criteria are missing or unsupported.

    • No prior approval through the plan's prior authorization process; submit as an initial evaluation instead.
    • No documented clinical benefit with Tezspire.
    • For severe asthma, the patient is not currently treated with, or compliant with, required asthma-control therapy within the past 90 days.
    • For CRSwNP, the patient will not continue standard nasal-polyp maintenance therapy with Tezspire.
    • The specialist or specialist-consultation requirement is not met.
    • The patient does not satisfy the concomitant immunomodulator requirements or has an FDA-labeled contraindication to Tezspire.
    • Renewal approval, when all requirements are met, is limited to 12 months.
    Emergency-room or urgent-care visit qualifies
    CRSwNP
    AbbreviationCRSwNP
    Full termChronic rhinosinusitis with nasal polyps
    Diagnostic contextDiagnosis may be confirmed by anterior rhinoscopy, nasal endoscopy, or computed tomography of the sinuses
    • At least 2 severe asthma exacerbations requiring systemic corticosteroid treatment occurred within the past 12 months.2 or more within the past 12 months
    • At least 1 serious asthma exacerbation requiring hospitalization, mechanical ventilation, an emergency-room visit, or an urgent-care visit occurred within the past 12 months.1 or more within the past 12 months
    • Controlled asthma worsens when inhaled and/or systemic corticosteroid doses are tapered.
    • Baseline FEV1 before therapy with Tezspire is less than 80% of predicted.< 80% of predicted
  18. The medication history, excluding sample use, indicates use within the past 12 months of a biologic immunomodulator that is FDA-labeled or supported in compendia for asthma.within the past 12 months
  19. CRSwNP

    • Qualifying symptoms

      • An adult patient has at least 2 qualifying symptoms: nasal discharge, nasal obstruction or congestion, facial pressure or pain, or loss or decreased sense of smell.at least 2 symptoms
      • A pediatric patient has at least 2 qualifying symptoms: nasal discharge, nasal obstruction or congestion, facial pressure or pain, or cough.at least 2 symptoms
    • Symptoms have been present for at least 12 consecutive weeks.at least 12 consecutive weeks
    • Diagnostic confirmation

      • Diagnosis is confirmed by anterior rhinoscopy.
      • Diagnosis is confirmed by nasal endoscopy.
      • Diagnosis is confirmed by sinus CT.
    • The patient tried and had an inadequate response to an intranasal corticosteroid.
  20. Age or evidence support

    • The patient's age is within FDA labeling for the requested indication.
    • There is support for using Tezspire for the patient's age and requested indication.
    • The indication and route are supported in compendia.

      Allowed compendia: AHFS; DrugDex level 1, 2a, or 2b; or NCCN recommended-use level 1, 2a, or 2b.

  21. Required background therapy

    • Inhaled-corticosteroid pathway for severe asthma

      • The patient is not currently treated with an asthma biologic and is currently treated with a maximally tolerated inhaled corticosteroid for at least 3 months with adherence for 90 days within the past 120 days.at least 3 months; adherent for 90 days within the past 120 days

        Chart notes required.

      • Patient currently treated with an asthma biologic

        • The patient is currently treated with an adequately dosed inhaled corticosteroid for at least 3 months with adherence for 90 days within the past 120 days.at least 3 months; adherent for 90 days within the past 120 days

          Chart notes required.

        • The patient is currently treated with a maximally tolerated inhaled corticosteroid for at least 3 months with adherence for 90 days within the past 120 days.at least 3 months; adherent for 90 days within the past 120 days

          Chart notes required.

      • The patient has an intolerance or hypersensitivity to one inhaled corticosteroid.
      • The patient has an FDA-labeled contraindication to all inhaled corticosteroids.
    • Additional controller for severe asthma

      • The patient has been treated for at least 3 months and has been adherent for 90 days within the past 120 days with a LABA, LAMA, LTRA, or theophylline.at least 3 months; adherent for 90 days within the past 120 days

        Chart notes required.

      • The patient has an intolerance or hypersensitivity to one LABA, LAMA, LTRA, or theophylline.
      • The patient has an FDA-labeled contraindication to all LABAs and LAMAs.
    • For severe asthma, the patient will continue asthma-control therapy in combination with Tezspire.
    • For CRSwNP, the patient is currently treated with and will continue standard nasal-polyp maintenance therapy in combination with Tezspire.

      Examples include nasal saline irrigation, intranasal corticosteroids such as fluticasone or mometasone nasal spray, or Sinuva.

  22. Specialist oversight

    • The prescriber is a specialist in the patient's diagnosis or has consulted with an appropriate specialist.

      Examples include an allergist, immunologist, pulmonologist, or otolaryngologist, as applicable.

  23. Concomitant immunomodulator use

    • The patient will not use Tezspire with another immunomodulatory agent.
    • The patient will use Tezspire with another immunomodulatory agent, the prescribing information does not limit the combination, and supporting clinical trials, phase III studies, or guidelines are submitted.
  24. Safety

    • The patient does not have an FDA-labeled contraindication to Tezspire.
  25. For CRSwNP, the patient will continue standard nasal-polyp maintenance therapy in combination with Tezspire.

    Examples include nasal saline irrigation, intranasal corticosteroids such as fluticasone or mometasone nasal spray, or Sinuva.

  26. The prescriber is a specialist in the patient's diagnosis or has consulted with an appropriate specialist.

    Examples include an allergist, immunologist, pulmonologist, or otolaryngologist, as applicable.

  27. Concomitant immunomodulator use

    • The patient will not use Tezspire in combination with another immunomodulatory agent.
    • The patient will use Tezspire with another immunomodulatory agent, the prescribing information does not limit the combination, and supporting clinical trials, phase III studies, or guidelines are submitted.
  28. The patient does not have an FDA-labeled contraindication to Tezspire.